FDA Class II Recall: Teva's Granix (tbo-filgrastim) Pulled Due to Stability Failure
Teva Pharmaceuticals USA, Inc. initiated a Class II recall of 34,636 cartons of Granix (tbo-filgrastim) Injection due to failed 12-month stability tests, with a known peptide below specification limits. This voluntary, nationwide recall impacts supply chains for a critical leukocyte growth factor, necessitating immediate action from procurement and regulatory teams to manage disruption and ensure patient safety.
FDA Initiates Class II Recall for Teva's Granix (tbo-filgrastim) Due to Stability Failure
Teva Pharmaceuticals USA, Inc. has initiated a voluntary Class II recall, designated D-0218-2025, for its Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL. This critical action, commenced on January 10, 2025, stems from a failure in the product's 12-month stability specifications, specifically reporting one of the known peptides to be below its defined limit. The recall impacts 34,636 cartons of this human prescription drug, which is a Granulocyte Colony-Stimulating Factor (G-CSF) used to increase myeloid cell production. For procurement directors, this means immediate action is required to identify and quarantine affected inventory. The recalled product, distributed nationwide across the United States, includes various packaging configurations: single syringes in cartons (NDC 63459-910-11, 63459-910-17) and ten-syringe cartons (NDC 63459-910-15). Regulatory affairs heads must ensure compliance with recall procedures and assess the impact on ongoing product availability. The affected lots are 135738, 137149, and 137148, all bearing an expiration date of September 30, 2025. This event underscores the imperative for stringent quality control throughout a product's shelf life.
Commercial and Regulatory Implications for Teva Pharmaceuticals USA, Inc.
The Class II classification of this recall signifies that while the use of the defective product may cause temporary or medically reversible adverse health consequences, the probability of serious adverse health consequences is remote. For Teva Pharmaceuticals USA, Inc., the distributor based in Parsippany, NJ, this voluntary, firm-initiated recall of Granix (tbo-filgrastim) carries significant commercial and regulatory weight. The manufacturing facility, UAB Teva Baltics in Vilnius, Lithuania, and the product's origin in Israel, will face heightened scrutiny regarding their quality management systems and stability testing protocols. Business development executives should anticipate potential disruptions to market supply and a need to rebuild confidence among healthcare providers and patients. Regulatory affairs teams at Teva must conduct a thorough root cause investigation into the stability failure and implement robust corrective and preventive actions (CAPAs) to prevent recurrence. Failure to adequately address the FDA's concerns could lead to further regulatory actions, including potential import alerts or additional inspections. This incident highlights the financial and reputational risks associated with deviations from established quality specifications for critical biologic therapies.
Mitigating Supply Chain Risk for Filgrastim-Based Therapies
This recall of Granix (tbo-filgrastim) serves as a critical reminder for supply chain VPs and procurement directors regarding the inherent risks in sourcing complex biologic drugs. Filgrastim, a leukocyte growth factor, is essential for patients requiring increased myeloid cell production. The stability failure of a known peptide in Granix underscores the necessity for comprehensive supplier qualification processes that include rigorous evaluation of stability data and manufacturing controls. Over-reliance on a single manufacturing site or supplier for such vital medicines can create significant vulnerabilities. Procurement teams should proactively review their existing supply agreements for filgrastim and other G-CSF products, ensuring that robust quality agreements are in place that mandate transparent reporting of stability data and deviations. Diversifying the supplier base, where feasible, can mitigate the impact of such recalls. Regulatory affairs heads should monitor the FDA's ongoing oversight of this recall and assess how similar stability issues might affect other products in their portfolio. This event reinforces the need for continuous vigilance in maintaining the integrity and resilience of global pharmaceutical supply chains.